After 11 months of dupilumab treatment, significant pigmented hair has grown across the patient’s scalp.
Massachusetts General Hospital (MGH) physicians are reporting an unexpected side-effect from treatment with dupilumab, which is FDA approved for the treatment of moderate to severe eczema, also called atopic dermatitis. In their case report published in JAMA Dermatology, the physicians describe how their 13-year-old patient, who has alopecia totalis – a total lack of scalp hair – along with eczema, experienced significant hair regrowth while being treated with dupilumab, a drug marketed under the brand name Dupixent.
“We were quite surprised since this patient hadn’t grown scalp hair since the age of 2, and other treatments that can help with hair loss did not in her case,” says Marya...
Read More
Recent Comments